IL1B and infection: Although anti‐IL‐1β treatment has shown significant therapeutic effect, long‐term inhibition of IL‐1β may increase infection risks.[5, 34] These blunt approaches focus on broad suppression of immune and inflammatory responses, but ignore intricate and specific regulation of the immune responses, potentially disrupting essential homeostatic and protective functions of immune system.[35] By contrast, selectively regulating immune processes promises safer and more efficacious outcomes.[6]